Analystreport

BioTime, Inc. (NASDAQ: BTX) had its "buy" rating re-affirmed by analysts at HC Wainwright.

Brooklyn ImmunoTherapeutics, Inc.  (BTX) 
NASDAQ:AMEX Investor Relations: biotimeinc.com/pexservice/investors